Replimune Group, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
REPL Nasdaq 2836 www.replimune.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Replimune Group, Inc.

Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months - Dec 31st, 2025 12:42 pm
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference - Dec 18th, 2025 6:00 am
Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025) - Nov 7th, 2025 2:45 pm
Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update - Nov 6th, 2025 6:00 am
Replimune Group (REPL) Is Up 86.2% After FDA Accepts Resubmitted RP1 Application for Advanced Melanoma—Has The Bull Case Changed? - Oct 22nd, 2025 12:22 pm
Trending tickers: HSBC, Cleveland-Cliffs, GSI Technology, Beyond Meat and Replimune - Oct 21st, 2025 2:33 am
A Look at Replimune Group’s (REPL) Valuation Following Promising IGNYTE Phase 2 Melanoma Trial Results - Oct 20th, 2025 11:06 pm
Why Replimune Stock Was Soaring Today - Oct 20th, 2025 2:10 pm
Wall Street Set to Open Higher Monday as Investors Look Ahead to a Week of Earnings Reports - Oct 20th, 2025 7:27 am
Investors Look Ahead to Key Earnings Reports as US Futures Rise Monday Pre-Bell - Oct 20th, 2025 6:01 am
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025 - Oct 19th, 2025 6:00 am
Replimune Group (REPL): Valuation in Focus After FDA Setback and Investor Lawsuit Announcements - Sep 20th, 2025 6:07 am
Why Replimune Stock Was Tumbling Again Today - Sep 19th, 2025 2:08 pm
Replimune Group (REPL) Nosedives 39% as FDA Approval for Melanoma Treatment ‘Uncertain’ - Sep 19th, 2025 8:12 am
Intel downgraded, Tesla upgraded: Wall Street's top analyst calls - Sep 19th, 2025 7:39 am
Why Replimune Stock Plummeted by Almost 40% Today - Sep 18th, 2025 4:59 pm
Replimune Provides Update Following Type A Meeting with FDA - Sep 18th, 2025 7:15 am
Replimune Announces Type A Meeting Scheduled with FDA - Sep 2nd, 2025 6:00 am
Controversial FDA regulator back 12 days after resigning - Aug 11th, 2025 9:01 am
Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update - Aug 7th, 2025 6:00 am